In September, the Food and Drug Administration will host a meeting on patient-focused drug treatment of idiopathic pulmonary fibrosis (IPF), according to an announcement from the Pulmonary Fibrosis Foundation.
“We applaud the FDA’s initiative to involve patients and advocates in the IPF drug development process and are grateful to the PF community for rallying to help make this happen. Nothing is more important to the PF community than the identification of new treatments and, ultimately, a cure for pulmonary fibrosis,” said David Lederer, MD, Senior Medical Advisor, Patient Communications, the Pulmonary Fibrosis Foundation.
“As the leading advocacy voice in our community, the PFF looks forward to working with the FDA in this process. We encourage patients and their caregivers to call or email our Patient Communication Center to let us know which symptoms and treatment approaches matter most to them.”
Click here for details on how to register for the meeting.
- Disorders & Diseases
- Public Health
- Products & Treatment
- Department Management
- Edition Archive